3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole | 1358779-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole
• 英文别名: 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]isoxazol；3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-oxazole
• CAS: 1358779-00-6
• 化学式: C₁₅H₁₈BNO₃
• 分子量: 271.124
• InChiKey: RHIGTXHZAUKKGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-4-(4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 、 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole 在 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 以43%的产率得到(2R)-4-[4-(4-isoxazol-3-ylphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide
  参考文献：
  名称：

  Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

  摘要：

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

  DOI：

  10.1021/jm2014875
• 作为产物：
  描述：

  3-(4-溴苯基)异噁唑 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 以93%的产率得到3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole
  参考文献：
  名称：

  Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

  摘要：

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

  DOI：

  10.1021/jm2014875

文献信息

• [EN] TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] TRIAZOLOPYRIDIN-3-ONES OU LEURS SELS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：YUHAN CORP

  公开号：WO2020121263A1

  公开（公告）日：2020-06-18

  The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

  目前的技术提供三唑吡啶-3-酮或其药用盐，其制备方法，包含它们的药物组合物，以及它们的用途。三唑吡啶-3-酮或其药用盐对VAP-1具有抑制活性，因此可以用于治疗和预防非酒精性脂肪性肝病（NASH）等疾病。
• Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections
  作者：Justin I. Montgomery、Matthew F. Brown、Usa Reilly、Loren M. Price、Joseph A. Abramite、Joel Arcari、Rose Barham、Ye Che、Jinshan Michael Chen、Seung Won Chung、Elizabeth M. Collantes、Charlene Desbonnet、Matthew Doroski、Jonathan Doty、Juntyma J. Engtrakul、Thomas M. Harris、Michael Huband、John D. Knafels、Karen L. Leach、Shenping Liu、Anthony Marfat、Laura McAllister、Eric McElroy、Carol A. Menard、Mark Mitton-Fry、Lisa Mullins、Mark C. Noe、John O’Donnell、Robert Oliver、Joseph Penzien、Mark Plummer、Veerabahu Shanmugasundaram、Christy Thoma、Andrew P. Tomaras、Daniel P. Uccello、Alfin Vaz、Donn G. Wishka

  DOI：10.1021/jm2014875

  日期：2012.2.23

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.